You are here

Launch Date Set for Eye Drug, Jetrea (Ocriplasmin)

First pharmacological treatment for vitreomacular adhesion (Jan. 4)

The U.S. launch date for Jetrea (ocriplasmin, ThromboGenics) has been set for January 14, 2013. Jetrea intravitreal injection is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion (VMA).

The drug’s recommended dose is 0.125 mg (0.1 mL) of the diluted solution administered by intravitreal injection to the affected eye once as a single injection. The U.S. price for a single-use glass vial is $3,950.

The FDA approved Jetrea in October 2012 as the first pharmacological agent for the treatment of symptomatic VMA. The approval was based on phase III data, which showed that Jetrea was significantly more effective than placebo in the treatment of symptomatic VMA (26.5% versus 10.1%, respectively; P

Symptomatic VMA is a progressive, sight-threatening condition that, when left untreated, often leads to retinal distortion, further deterioration in vision, and irreversible damage to eyesight.

Source: ThromboGenics; January 4, 2013.

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs